Client zone

A Novel Drug-Device Combination Product Using Terumo’s Automated Injection Device Completes Clinical Study in Japan

Aiming to Reduce the Burden on Patients Receiving Ambulatory Chemotherapy


Terumo Corporation (TSE: 4543) today announced the completion of a clinical study in Japan for a product using Terumo’s automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin).

Kyowa Kirin initiated the clinical study in February 2020, to evaluate the safety of the product which combines the drug G-Lasta® (generic name: pegfilgrastim (genetical recombination)) and an automated injection device.

G-Lasta is a drug for decreasing incidence of febrile neutropenia in patients receiving cancer chemotherapy, launched in Japan by Kyowa Kirin in 2014. The drug is generally administered at hospitals, at least one day after chemotherapy.

This investigational product has a function to deliver G-Lasta into the patient’s body after a specified time. By applying the device on the same day of chemotherapy, it is expected to alleviate the patient’s burden of revisiting the hospital, and also reduce the workload of healthcare providers.

Terumo’s Alliance Division, a part of the General Hospital Company, is committed to developing partnerships with pharmaceutical companies. Based on Terumo’s expertise on injection needles, syringes and other core technologies related to drug administration, the company will continue to meet the expanding needs of healthcare by developing novel drug delivery systems. Moving forward, Terumo will strive to promote an even better future for healthcare together with pharmaceutical companies.



Referral Scheme

Candidate Tools

Join our Mailing list

G2 Academy

Contact Us

We offer a national recruitment service from our Surrey head office, please see contact details below.

Head Office

PM House,
Riverway Estate
Old Portsmouth Rd

T: 01483 910 940

  • 16
  • Aug 2021

Gates & Soros buy UK-based Mologic: A social enterprise to improve global healthcare

Read More

for Us

Find out More